Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
Provided By GlobeNewswire
Last update: Jan 28, 2025
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) domain fusion proteins
Read more at globenewswire.comNASDAQ:SONN (2/21/2025, 8:00:02 PM)
1.44
+0.01 (+0.7%)
Find more stocks in the Stock Screener
